{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-24-000002","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.784577+00:00","generated_at":"2026-06-05T10:57:22.865466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xencor Q4 2023 net loss $19.1M ($0.31 EPS); cash $697.4M; workforce cut ~10%","bullets":["Q4 2023 revenue $44.7M vs $21.6M YoY; full-year net loss $126.1M ($2.08) vs $55.2M ($0.93) in 2022.","Cash and marketable securities $697.4M at Dec 31, 2023; guidance for end-2024 $475M-$525M, runway into 2027.","Vudalimab in high-risk mCRPC showed 33% ORR (4/12) and PSA90 in 25%; plans to advance or decide by H1 2025.","J&J milestones: $27.5M in Q4 2023; two new CD28 candidates selected; workforce cut ~10% in Jan 2024.","Pausing cytokine programs XmAb564 (IL2-Fc) and XmAb662 (IL12-Fc) after data review; dosing first patient for XmAb541 in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-24-000002","json":"https://secwatch.observer/filing/0001326732-24-000002.json","markdown":"https://secwatch.observer/filing/0001326732-24-000002.md","text":"https://secwatch.observer/filing/0001326732-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000002/0001326732-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000002/xncr-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T10:57:22.865466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"994f168c1b9434b9fc47807535beb2354c68ec79","claim":"Xencor Inc reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Xencor, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673224000002/0001326732-24-000002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}